Lauren Sullivan, MD
Pulmonary Disease · Charleston, SCNPI 1528420528
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $379 of the $519 with a category attached, or 73.0%. 6 manufacturers reported payments, led by Boehringer Ingelheim at 33.7% of the total. 2025 is the largest year on record at $208, more than ten times the $9 reported in 2019. That places this record below the midpoint for pulmonary disease clinicians in SC, where the typical reported total is $2,769.
Across 7 payments — averaging $74.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$175
- ZOLL Respicardia, Inc.$152
- Insmed, Inc.$87
- Baxter Healthcare$63
- Aimmune Therapeutics, Inc.$33
- SPR Therapeutics, Inc$9
Across 17 payments — averaging $3313.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Verona Pharma, Inc.$56K
What the payments were for
- Travel & lodging$14027%
- Food & beverage$37973%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 2 | $175 |
| ZOLL Respicardia, Inc. | 1 | $152 |
| Insmed, Inc. | 1 | $87 |
| Baxter Healthcare | 1 | $63 |
| Aimmune Therapeutics, Inc. | 1 | $33 |
| SPR Therapeutics, Inc | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- remede System$152
How this compares
$519 in reported general payments places this provider in the 20th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 11 | $40,008 |
| BreynaBudesonide/Formoterol Fumarate | 17 | $2,636 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $662 |
| Ethambutol Hcl | 11 | $528 |
| Azithromycin | 13 | $353 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Charleston
- Patrick FlumeCharleston$418K
- Gerard SilvestriCharleston$254K
- Denise Gabrielle SeseCharleston$51K
- Timothy WhelanCharleston$41K
- Marc JudsonCharleston$28K
- John HugginsCharleston$18K
- John CoxCharleston$16K
- Adam FoxCharleston$13K
- Michael SpandorferCharleston$12K
- Rachana KrishnaCharleston$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.